Efzimfotase Alfa Granted Priority Review in the US as Treatment for Patients with Hypophosphatasia Aged 2 Years and Older

BLA Filingefzimfotase alfaPositive

AI Analysis

Summary

Alexion's efzimfotase alfa received Priority Review designation from the FDA for treating hypophosphatasia in patients aged 2 years and older. This regulatory milestone accelerates the development pathway for the rare disease therapeutic.

Outcome Details

Priority Review granted by FDA

Importance:7/10

Sentiment:

0.80

rare_diseasepriority_reviewFDA_regulatoryBLAhypophosphatasia

Related Companies

$AZN $AZN

Read the original article

Published by Drugs.com Clinical Trial Results on September 18, 2026 10:09 PM

Read Original